WE ARE ABOUT TO ENTER THE GOLDEN AGE OF GENE THERAPY

Summary from the TLDR newsletter

The first CRISPR-based gene therapies were approved in the UK and the US late last year. While gene therapies promise to tackle both rare and common diseases, they will come with side effects like exorbitant prices, barriers to access, and ethical concerns. This article looks at how the field promises to bring better editing with more targets and equitable therapies for all in 2024 and beyond.